Endo Pharmaceuticals  
 
 
Products Overview
Products in Development
Pain Management
Education Tools
Health Links
   

Healthcare Professionals - Products in Development

This product information is intended for U.S. residents only. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product outside the United States.

Endo's pipeline portfolio is primarily comprised of products intended to address acute, chronic and neuropathic pain conditions and closely allied therapeutic areas such as neurology (FrovaŽ) and supportive care oncology (EN 3285).

Product in Development

Therapeutic Target

Development Stage
Frova® (frovatriptan)
Long-acting triptan (selective serotonin receptor agonist)
(Exclusive North American marketing rights licensed from Vernalis Development Limited)		 Prophylaxis for menstrual migraine Supplemental New Drug Application (sNDA) filed July 19, 2006; non-approvable letter issued September 2007
EN 3267 - Rapinyl™
Oral, fast-dissolving tablet of fentanyl for sublingual administration (Exclusive North American marketing and development rights licensed from Orexo AB)		 Breakthrough cancer pain Phase III
EN 3269 - Topical Ketoprofen Patch
(Exclusive U.S. and Canadian development and commercialization rights licensed from ProEthic Pharmaceuticals, Inc.) 		Localized treatment of acute pain associated with soft-tissue injuries such as tendonitis or joint sprains and strains Phase III
EN 3285 - NAC Oral Rinse
(Topical oral-rinse formulation)		 Oral mucositis Phase III
EN 3270 - Transdermal Sufentanil Patch (Exclusive U.S. and Canadian development and commercialization rights licensed from DURECT Corporation) Moderate-to-severe chronic pain for up to seven days Phase II
EN 3294
(StaccatoŽ fentanyl) (Exclusive North American development and commercialization rights licensed from Alexza Pharmaceuticals, Inc.) 		Breakthrough cancer and non-cancer pain Phase I

    Privacy/Legal © 2008 Endo Pharmaceuticals   All Rights Reserved.